LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU=Fiandaca Massimo S
  2. AU="Belli, Sara"
  3. AU="Capogiri, Monica"
  4. AU="Al-Hattab, Eyad"
  5. AU="Hou, Tsung-Wei"
  6. AU="Meng, Ying Shirley"
  7. AU="Emanuele Rezoagli"
  8. AU="Verhagen, M A M T"
  9. AU="Haden, Kathleen"
  10. AU="Lee, Ju Yup"
  11. AU="Camilla Caimi"
  12. AU="Huynh, Nancy"
  13. AU="Sun, Weilin"
  14. AU="Whalon, Mark E."
  15. AU=Grishunin Kirill
  16. AU="Quaranta, Gianluigi"
  17. AU="Jitaroon, Kawinyarat"
  18. AU="Anderson, Eric C"
  19. AU="Thiyagarajan, Kamalraj"
  20. AU="Simnica, Donjetë"

Suchergebnis

Treffer 1 - 10 von insgesamt 52

Suchoptionen

  1. Artikel ; Online: Perspective: Striving Toward Reproducible Results in Blood-based Metabolomic Investigations for Brain Disorders.

    Fiandaca, Massimo S

    Current topics in medicinal chemistry

    2018  Band 18, Heft 15, Seite(n) 1271–1273

    Mesh-Begriff(e) Animals ; Biomarkers/blood ; Blood-Brain Barrier/metabolism ; Brain Diseases/blood ; Brain Diseases/diagnosis ; Brain Diseases/metabolism ; Humans ; Metabolomics
    Chemische Substanzen Biomarkers
    Sprache Englisch
    Erscheinungsdatum 2018-12-31
    Erscheinungsland United Arab Emirates
    Dokumenttyp Journal Article
    ZDB-ID 2064823-6
    ISSN 1873-4294 ; 1568-0266
    ISSN (online) 1873-4294
    ISSN 1568-0266
    DOI 10.2174/156802661815181101110212
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel: Foetal bovine serum influence on in vitro extracellular vesicle analyses.

    Lehrich, Brandon M / Liang, Yaxuan / Fiandaca, Massimo S

    Journal of extracellular vesicles

    2021  Band 10, Heft 3, Seite(n) e12061

    Mesh-Begriff(e) Cell Culture Techniques/methods ; Extracellular Vesicles/drug effects ; Extracellular Vesicles/metabolism ; Serum Albumin, Bovine/pharmacology
    Chemische Substanzen Serum Albumin, Bovine (27432CM55Q)
    Sprache Englisch
    Erscheinungsdatum 2021-01-25
    Erscheinungsland United States
    Dokumenttyp Editorial ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 2683797-3
    ISSN 2001-3078
    ISSN 2001-3078
    DOI 10.1002/jev2.12061
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: Response to "Technical approaches to reduce interference of Fetal calf serum derived RNA in the analysis of extracellular vesicle RNA from cultured cells".

    Lehrich, Brandon M / Liang, Yaxuan / Fiandaca, Massimo S

    Journal of extracellular vesicles

    2019  Band 8, Heft 1, Seite(n) 1599681

    Sprache Englisch
    Erscheinungsdatum 2019-04-14
    Erscheinungsland Sweden
    Dokumenttyp Journal Article
    ZDB-ID 2683797-3
    ISSN 2001-3078
    ISSN 2001-3078
    DOI 10.1080/20013078.2019.1599681
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.

    Rocco, Matthew T / Akhter, Asad S / Ehrlich, Debra J / Scott, Gretchen C / Lungu, Codrin / Munjal, Vikas / Aquino, Anthony / Lonser, Russell R / Fiandaca, Massimo S / Hallett, Mark / Heiss, John D / Bankiewicz, Krystof S

    Molecular therapy : the journal of the American Society of Gene Therapy

    2023  Band 31, Heft 7, Seite(n) 2296

    Sprache Englisch
    Erscheinungsdatum 2023-04-24
    Erscheinungsland United States
    Dokumenttyp Published Erratum
    ZDB-ID 2010592-7
    ISSN 1525-0024 ; 1525-0016
    ISSN (online) 1525-0024
    ISSN 1525-0016
    DOI 10.1016/j.ymthe.2023.04.009
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Plasma Sphingomyelins in Late-Onset Alzheimer's Disease.

    Fote, Gianna / Wu, Jie / Mapstone, Mark / Macciardi, Fabio / Fiandaca, Massimo S / Federoff, Howard J

    Journal of Alzheimer's disease : JAD

    2021  Band 83, Heft 3, Seite(n) 1161–1171

    Abstract: ... Specimens from control, preclinical, and symptomatic subjects were analyzed using targeted mass ...

    Abstract Background: Altered plasma levels of sphingolipids, including sphingomyelins (SM), have been found in mouse models of Alzheimer's disease (AD) and in AD patient plasma samples.
    Objective: This study assesses fourteen plasma SM species in a late-onset AD (LOAD) patient cohort (n = 138).
    Methods: Specimens from control, preclinical, and symptomatic subjects were analyzed using targeted mass-spectrometry-based metabolomic methods.
    Results: Total plasma SM levels were not significantly affected by age or cognitive status. However, one metabolite that has been elevated in manifest AD in several recent studies, SM OHC14:1, was reduced significantly in pre-clinical AD and MCI relative to normal controls.
    Conclusion: We recommend additional comprehensive plasma lipidomics in experimental and clinical biospecimens related to LOAD that might advance the utility of plasma sphingomyelin levels in molecular phenotyping and interpretations of pathobiological mechanisms.
    Mesh-Begriff(e) Aged, 80 and over ; Alzheimer Disease/blood ; Asymptomatic Diseases ; Cohort Studies ; Female ; Humans ; Male ; Mass Spectrometry ; Metabolomics ; Sphingolipids/blood
    Chemische Substanzen Sphingolipids
    Sprache Englisch
    Erscheinungsdatum 2021-08-16
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-200871
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel: Advancing gene therapies, methods, and technologies for Parkinson's Disease and other neurological disorders.

    Fiandaca, Massimo S / Lonser, Russell R / Elder, J Bradley / Ząbek, Mirosław / Bankiewicz, Krystof S

    Neurologia i neurochirurgia polska

    2020  Band 54, Heft 3, Seite(n) 220–231

    Abstract: Introduction: Vector-based intracerebral gene therapies are being used to treat specific neurodegenerative conditions such as Parkinson's Disease (PD). This review presents a basis for central nervous system (CNS) gene therapy treatments of ... ...

    Abstract Introduction: Vector-based intracerebral gene therapies are being used to treat specific neurodegenerative conditions such as Parkinson's Disease (PD). This review presents a basis for central nervous system (CNS) gene therapy treatments of neurodegenerative diseases such as PD, as well as the need for novel skill sets and health delivery strategies within the clinical neurosciences (neurology and neurosurgery) to meet future demand for such therapies.
    State of the art: Preclinical vector-based gene therapy approaches have been translated into clinical trials for PD and other neurodegenerative conditions. Unfortunately, such trials, and parallel efforts using other therapeutics, have yet to provide a breakthrough. Image-guided convection enhanced delivery (CED) optimises the parenchymal distribution of gene therapies applied within the CNS, and may ultimately provide such a breakthrough.
    Clinical implications: Currently, image-guided CED and gene therapy are not part of training programmes for most neurosurgeons and neurologists. As a result, few medical centres and hospitals have sufficiently experienced teams to participate in gene transfer clinical trials for PD or other neurological conditions. If CNS gene therapies prove to be efficacious for PD and/or other conditions, the demand for such treatments will overwhelm the available number of experienced clinical neuroscience teams and treatment centres.
    Future directions: Expanded indications and demand for CNS gene therapies will require a worldwide educational effort to supplement the training of clinical neuroscience practitioners. Initially, a limited number of Centres of Excellence will need to establish relevant educational training requirements and best practice for such therapeutic approaches. Advanced technologies, including robotics and artificial intelligence, are especially germane in this regard, and will expand the treatment team's capabilities while assisting in the safe and timely care of those afflicted.
    Mesh-Begriff(e) Artificial Intelligence ; Central Nervous System ; Genetic Therapy ; Humans ; Parkinson Disease/genetics ; Parkinson Disease/therapy
    Sprache Englisch
    Erscheinungsdatum 2020-06-18
    Erscheinungsland Poland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 415519-1
    ISSN 1897-4260 ; 0028-3843
    ISSN (online) 1897-4260
    ISSN 0028-3843
    DOI 10.5603/PJNNS.a2020.0046
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: New Experimental and Computational Tools for Drug Discovery: From Chemistry to Biology. Metabolomics, Pharmacokinetics, and Medicinal Chemistry. Part - IV.

    Fiandaca, Massimo S / Gonzalez-Dominguez, Raul / Gonzalez-Diaz, Humbert

    Current topics in medicinal chemistry

    2018  Band 18, Heft 11, Seite(n) 881–882

    Mesh-Begriff(e) Chemistry, Pharmaceutical ; Combinatorial Chemistry Techniques ; Computational Biology ; Drug Discovery ; Metabolomics ; Proteomics
    Sprache Englisch
    Erscheinungsdatum 2018-09-05
    Erscheinungsland United Arab Emirates
    Dokumenttyp Editorial ; Introductory Journal Article
    ZDB-ID 2064823-6
    ISSN 1873-4294 ; 1568-0266
    ISSN (online) 1873-4294
    ISSN 1568-0266
    DOI 10.2174/156802661811180808095053
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Using viral-mediated gene delivery to model Parkinson's disease: do nonhuman primate investigations expand our understanding?

    Fiandaca, Massimo S / Federoff, Howard J

    Experimental neurology

    2014  Band 256, Seite(n) 117–125

    Abstract: In this review, we consider the use of nonhuman primate (NHP) models of Parkinson's disease (PD) produced using viral-mediated gene delivery and information they provide in comparison to other model systems in rodents and NHPs. To date, rodent and NHP PD ...

    Abstract In this review, we consider the use of nonhuman primate (NHP) models of Parkinson's disease (PD) produced using viral-mediated gene delivery and information they provide in comparison to other model systems in rodents and NHPs. To date, rodent and NHP PD models have found it difficult to fully recapitulate the human disorder and, therefore, provide little actual insight into disease progression. The viral-mediated gene delivery method for α-synuclein has been shown to produce a parkinsonian rodent and NHP. This novel viral-mediated gene transfer model in the NHP appears to provide a significant advance beyond neurotoxicant models, by more closely mimicking the more chronic time course of developed behavioral deterioration and neuropathology. Although we agree that the use of these novel methods inducing parkinsonian NHPs may provide relevant treatment insights, beyond those of more standard PD models, we remain cautious as to the preclinical models' ability to predict outcomes in human trials. In specific cases of certain novel medical therapeutics, therefore, we also consider the phase 0 clinical trial as offering an alternative to the currently non-predictive preclinical models, including those in the NHP.
    Mesh-Begriff(e) Animals ; Disease Models, Animal ; Gene Transfer Techniques ; Macaca/genetics ; Parkinson Disease/genetics ; Parkinson Disease/pathology ; alpha-Synuclein/genetics
    Chemische Substanzen alpha-Synuclein
    Sprache Englisch
    Erscheinungsdatum 2014-06
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 207148-4
    ISSN 1090-2430 ; 0014-4886
    ISSN (online) 1090-2430
    ISSN 0014-4886
    DOI 10.1016/j.expneurol.2013.03.014
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Author Correction: Plasma microRNA markers of upper limb recovery following human stroke.

    Edwardson, Matthew A / Zhong, Xiaogang / Fiandaca, Massimo S / Federoff, Howard J / Cheema, Amrita K / Dromerick, Alexander W

    Scientific reports

    2020  Band 10, Heft 1, Seite(n) 2484

    Abstract: An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    Abstract An amendment to this paper has been published and can be accessed via a link at the top of the paper.
    Sprache Englisch
    Erscheinungsdatum 2020-02-07
    Erscheinungsland England
    Dokumenttyp Published Erratum
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-020-58943-2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.

    Rocco, Matthew T / Akhter, Asad S / Ehrlich, Debra J / Scott, Gretchen C / Lungu, Codrin / Munjal, Vikas / Aquino, Anthony / Lonser, Russell R / Fiandaca, Massimo S / Hallett, Mark / Heiss, John D / Bankiewicz, Krystof S

    Molecular therapy : the journal of the American Society of Gene Therapy

    2022  Band 30, Heft 12, Seite(n) 3632–3638

    Abstract: Direct putaminal infusion of adeno-associated virus vector (serotype 2) (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene was studied in a phase I clinical trial of participants with advanced Parkinson's disease (PD) ...

    Abstract Direct putaminal infusion of adeno-associated virus vector (serotype 2) (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene was studied in a phase I clinical trial of participants with advanced Parkinson's disease (PD). Convection-enhanced delivery of AAV2-GDNF with a surrogate imaging tracer (gadoteridol) was used to track infusate distribution during real-time intraoperative magnetic resonance imaging (iMRI). Pre-, intra-, and serial postoperative (up to 5 years after infusion) MRI were analyzed in 13 participants with PD treated with bilateral putaminal co-infusions (52 infusions in total) of AAV2-GDNF and gadoteridol (infusion volume, 450 mL per putamen). Real-time iMRI confirmed infusion cannula placement, anatomic quantification of volumetric perfusion within the putamen, and direct visualization of off-target leakage or cannula reflux (which permitted corresponding infusion rate/cannula adjustments). Serial post-treatment MRI assessment (n = 13) demonstrated no evidence of cerebral parenchyma toxicity in the corresponding regions of AAV2-GDNF and gadoteridol co-infusion or surrounding regions over long-term follow-up. Direct confirmation of key intraoperative safety and efficacy parameters underscores the safety and tissue targeting value of real-time imaging with co-infused gadoteridol and putative therapeutic agents (i.e., AAV2-GDNF). This delivery-imaging platform enhances safety, permits delivery personalization, improves therapeutic distribution, and facilitates assessment of efficacy and dosing effect.
    Mesh-Begriff(e) Humans ; Parkinson Disease/diagnostic imaging ; Parkinson Disease/genetics ; Parkinson Disease/therapy ; Magnetic Resonance Imaging
    Sprache Englisch
    Erscheinungsdatum 2022-08-10
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Intramural
    ZDB-ID 2010592-7
    ISSN 1525-0024 ; 1525-0016
    ISSN (online) 1525-0024
    ISSN 1525-0016
    DOI 10.1016/j.ymthe.2022.08.003
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang